Clinical Trial

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this trial is to test whether patients with stage III papillary renal cell carcinoma (pRCC) could benefit from adjuvant therapy or not. The investigators invented a multi-classifier system that was successfully categorise patients with stage III pRCC into high-risk and low-risk groups. Here the investigators randomly assign classifier-defined high risk patients of stage III pRCC into adjuvant pembrolizumab group placebo group. Disease-free survival and overall survival are the end points of observation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-20.
Trial Details
NCT Number NCT06146777
Lead Sponsor First Affiliated Hospital, Sun Yat-Sen University
Conditions Papillary Renal Cell Carcinoma
Enrollment 468 participants
Start Date 2023-12-01
Primary Completion 2030-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2023-11-29